NZ596674A - Use of pufas to treat nerve damage - Google Patents

Use of pufas to treat nerve damage

Info

Publication number
NZ596674A
NZ596674A NZ596674A NZ59667410A NZ596674A NZ 596674 A NZ596674 A NZ 596674A NZ 596674 A NZ596674 A NZ 596674A NZ 59667410 A NZ59667410 A NZ 59667410A NZ 596674 A NZ596674 A NZ 596674A
Authority
NZ
New Zealand
Prior art keywords
pufas
decreased
nerve damage
treat nerve
tingling
Prior art date
Application number
NZ596674A
Other languages
English (en)
Inventor
Adam Kelliher
Angus Morrison
Norman Cameron
Phil Knowles
Original Assignee
Equateq Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Equateq Ltd filed Critical Equateq Ltd
Publication of NZ596674A publication Critical patent/NZ596674A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NZ596674A 2009-05-01 2010-04-22 Use of pufas to treat nerve damage NZ596674A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0907601.9A GB0907601D0 (en) 2009-05-01 2009-05-01 Novel methods
PCT/GB2010/000817 WO2010125330A1 (en) 2009-05-01 2010-04-22 Use of pufas to treat nerve damage

Publications (1)

Publication Number Publication Date
NZ596674A true NZ596674A (en) 2013-09-27

Family

ID=40792178

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ596674A NZ596674A (en) 2009-05-01 2010-04-22 Use of pufas to treat nerve damage

Country Status (14)

Country Link
US (1) US20120122982A1 (https=)
EP (1) EP2424519A1 (https=)
JP (1) JP5608220B2 (https=)
KR (1) KR101664518B1 (https=)
CN (1) CN102448453B (https=)
AU (1) AU2010243368C1 (https=)
BR (1) BRPI1009922A2 (https=)
CA (1) CA2762009C (https=)
GB (1) GB0907601D0 (https=)
MX (1) MX2011011615A (https=)
NZ (1) NZ596674A (https=)
SG (1) SG175848A1 (https=)
WO (1) WO2010125330A1 (https=)
ZA (1) ZA201108571B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
EP3068757B1 (en) * 2013-11-15 2019-02-27 DS Biopharma Limited Lysine salt of 15-hydroxy-8(z),11(z),13(e)-eicosatrienoic acid
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0065393B1 (en) * 1981-05-12 1984-12-27 Imperial Chemical Industries Plc Pyrrole derivatives
US4532254A (en) * 1983-03-17 1985-07-30 Kaken Pharmaceutical Co., Ltd. Inhibitor of aldose reductase
EP0335979A4 (en) * 1987-09-16 1992-02-26 Taiho Pharmaceutical Company, Limited Thienopyrimidine derivatives
PT707487E (pt) * 1993-06-09 2004-08-31 Martek Biosciences Corp Metodos e composicoes farmaceuticas uteis no tratamento de disturbios neurologicos
US7015249B1 (en) * 1997-12-12 2006-03-21 Purdue Research Foundation Methods and compositions for treating diabetes
US6107349A (en) * 1998-04-16 2000-08-22 Mantynen; Philip R. Method and composition for treating psoriasis
GB9827391D0 (en) * 1998-12-11 1999-02-03 Fundation O N C F Aldose reductase inhibitors and pharmaceutical compositions
CA2304906A1 (en) * 2000-04-07 2001-10-07 1411198 Ontario Limited 13-hode, a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia
WO2001083427A1 (en) * 2000-04-28 2001-11-08 Sankyo Company, Limited PPARη MODULATORS
EP1236720B1 (en) * 2001-02-28 2005-06-15 Pfizer Products Inc. Sulfonyl pyridazinone compounds useful as aldose reductase inhibitors
WO2002101392A2 (en) * 2001-06-08 2002-12-19 Xenon Genetics, Inc. Methods for treating disorders of the nervous and reproductive systems
US7410955B2 (en) * 2002-03-25 2008-08-12 Biosynergen, Inc. Therapeutic use of agonist ligands specific to G2A receptor
JP4972745B2 (ja) * 2005-06-22 2012-07-11 国立大学法人群馬大学 Ｇタンパク質共役型受容体ｇ２ａの作動薬、及びｇ２ａ活性調節薬のスクリーニング方法
JP5366211B2 (ja) * 2007-12-18 2013-12-11 国立大学法人富山大学 アルドース還元酵素阻害活性を有する縮合三環化合物

Also Published As

Publication number Publication date
ZA201108571B (en) 2013-01-30
JP5608220B2 (ja) 2014-10-15
CA2762009A1 (en) 2010-11-04
CN102448453B (zh) 2016-07-06
KR101664518B1 (ko) 2016-10-11
WO2010125330A1 (en) 2010-11-04
JP2012525362A (ja) 2012-10-22
MX2011011615A (es) 2012-01-27
SG175848A1 (en) 2011-12-29
CN102448453A (zh) 2012-05-09
KR20120023729A (ko) 2012-03-13
US20120122982A1 (en) 2012-05-17
EP2424519A1 (en) 2012-03-07
AU2010243368C1 (en) 2014-04-03
AU2010243368B2 (en) 2013-10-24
GB0907601D0 (en) 2009-06-10
BRPI1009922A2 (pt) 2016-03-15
AU2010243368A1 (en) 2011-12-15
CA2762009C (en) 2016-11-22

Similar Documents

Publication Publication Date Title
GT200600045A (es) Derivados de piridizina y su uso como agentes terapeuticos
NZ627780A (en) Adjustable elastic profile compression garment
EA201071038A1 (ru) Производные 1-бензил-3-гидроксиметилиндазола и их применение для лечения заболеваний, основанных на экспрессии mcp-1, cx3cr1 и p40
EA200800538A1 (ru) Терапевтические соединения
UY28860A1 (es) Procedimiento para el tratamiento de trastornos premenstruales y otros trastornos sexuales femeninos
EA200802412A1 (ru) Терапевтические комбинации для сопровождающихся болью медицинских состояний
MY161197A (en) Method for using a bacillus subtilis strain for prophylaxis and treatment of gastro-intestinal conditions
MX2010001449A (es) Bromhidrato de bupropion y aplicaciones terapeuticas.
PH12013500857A1 (en) Methods and compositions for treating hiv-associated diarrhea
AR075413A1 (es) Composiciones y metodo para usar aminopiridinas metodo para tratar la esclerosis multiple
MX2009009133A (es) Composiciones medicinales mejoradas que comprenden buprenorfina y naloxona.
ATE457729T1 (de) Verwendung von allopurinol zur behandlung von palmarer/plantarer erythrodysästhesie
NZ596674A (en) Use of pufas to treat nerve damage
SE0400184D0 (sv) New therapeutical use
NZ597003A (en) Orthotic sock
PH12012501461A1 (en) Apparatus for reducing symptoms of neurodegenerative diseases
EA201400423A1 (ru) Фармацевтические препараты и их применение при лечении половой дисфункции у женщин
MX2011007885A (es) Formulaciones de emulsion de narcoticos para tratamiento de dolor por cancer.
EA201071350A1 (ru) Композиции и способы для лечения воспаления роговицы
WO2004064779A3 (en) Use of nitroglycerin to relieve nocturnal muscle cramps
MX2008015323A (es) Composicion farmaceutica que comprende ciclobenzaprina y aceclofenac en asociacion.
EA201000672A1 (ru) Комбинезон для нейроортопедической реабилитации
SG153698A1 (en) Composition and method for prevention and treatment of alzheimeræs disease
EA200802136A1 (ru) Лечение меланомы
ATE368473T1 (de) Behandlung von abweichungen der ersten metatarsophalangealen verbindung des fusses

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 22 APR 2017 BY CPA GLOBAL

Effective date: 20140306

LAPS Patent lapsed